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ABSTRACT A clinical decision report using: 
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development 
and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes 
Endocrinol. 2015;3(11):866-875. https://doi.org/10.1016/S2213-8587(15)00291-0 
for a patient with pre-diabetes who is concerned about the prevention of microvascular complications through lifestyle intervention 
while managing her busy schedule as a traveling house cleaner. 
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Clinical-Social Context 
Susan Berry (pseudonym) is a 57-year-old Caucasian female that presents to the family medicine clinic for follow 
up on her prediabetes. Ms. Berry was diagnosed with prediabetes three months prior with a A1c of 6.3 and has 
since attempted to manage her condition with diet and exercise. She has an additional medical history of 
hypertension, hyperlipidemia, and obesity (BMI 40.42 kg/m2) that she manages with losartan, 
hydrochlorothiazide, and atorvastatin. She has no neuropathy, nephropathy, or retinopathy thus far. Ms. Berry is 
highly motivated to prevent the further development of diabetes and expressed her concern of watching her sister 
struggle with “constant pain and tingling in her feet” and “squeezing in” podiatry appointments in her busy 
schedule. She is also aware that diabetes can impair her vision and her kidneys and would also like to avoid these 
complications. She cites socioeconomic barriers including financial difficulty, few social supports, and time 
constraints to purchasing and preparing healthy meals with her employment as a traveling house cleaner. She 
currently has difficulty exercising and eats mostly fast food or frozen dinners because of her busy schedule. She is 
motivated to change her lifestyle and would like to avoid medications as much as possible. Her primary care team 
wondered about the comparative efficacy in lifestyle intervention or metformin to help Ms. Berry prevent the 
long-term diabetic complications that concern her while taking into consideration the socioeconomic barriers that 
she faces in this endeavor. 
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Clinical Question 
Does lifestyle intervention have a greater benefit than metformin in reducing long-term diabetic complications in patients with 
socioeconomic barriers to healthy living? 
Research Article 
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development 
and microvascular complications over 15-year follow-up: The Diabetes Prevention Program Outcomes Study. Lancet Diabetes 
Endocrinol. 2015;3(11):866-875. https://doi.org/10.1016/S2213-8587(15)00291-0 1 
Description of Related Literature 
Utilizing PubMed Advanced Search Builder, title and abstract terms that included “metformin” AND “lifestyle” AND “diabetes” AND 
“adult” AND “complications” yielded 157 citations with the “best match filter”. Subsequently, the randomized controlled trial filter 
was applied yielding 44 total citations since November 2020. The clinical queries and similar articles options on PubMed were 
utilized to ensure all relevant articles were reviewed. The abstracts of all 44 of these citations were preliminarily reviewed, and 33 
were omitted because they were not relevant to our clinical question or did not involve populations that were related to our patient. 
For example, some were specific to pregnant women, HIV patients, obese adolescents etc. Of the remaining 11 articles reviewed, 6 
were based on the data collected in the Diabetes Prevention Program (DPP).2 The related articles feature on Google Scholar was 
then used to source additional literature. The DPP, DPPOS, and ePREDICE trials were first to appear. Similar to Pubmed, other 
articles were reviews regarding the DPPOS trial or did not examine an applicable population of interest.  
The DPP was a large, randomized control trial involving 3234 adults at high risk for development of type 2 diabetes.2 The study had 
an average follow up of 2.8 years with a focus on diabetes incidence. The group was able to postulate that lifestyle intervention may 
possibly delay or prevent the development of diabetes-related complications. The articles examined in this query further examined 
the DPP to examine autonomic nervous system function3, risk of progression to diabetes4–6, the development of urinary 
incontinence7, and cardiovascular risk.8 However, the duration of follow-up in the DPP was too short to evaluate these relationships 
in a clinically relevant way. 
The DPP Outcomes Study (DPPOS) was a 15-year follow-up to the DPP that focused on microvascular complications related to 
diabetes.1 Two articles selected for evaluation in our narrowed search examined the DPPOS for diabetes incidence9 and 
depression.10 The ePREDICE trial also published its protocol and recruitment for the early prevention of microvascular complications 
in hyperglycemic patients but have yet to finalize its results.11 Based on these criteria, the DPPOS1 is the most current study relevant 
to the concerns of our patient and is evaluating the most efficacious treatment plan to optimize her long-term prognosis. It is also 
the only randomized control trial examining the comparison between lifestyle intervention and metformin on the development of 
long-term microvascular complications which include quality of life-related outcomes such as neuropathy. As such, this study was 
examined to answer our clinical question and how its result could be applied in the clinical management of Ms. Berry.  
Per the strength of recommendation taxonomy (SORT)12, this is a Grade of Recommendation Strength B based on the lack of 
multiple randomized control trials examining metformin compared to lifestyle for the prevention of microvascular diabetes related 
complications. 
Critical Appraisal 
The DPPOS1 was a cohort study in which patients enrolled in the DPP2 were evaluated in their respective treatment arms for 15 
years of follow-up. The DPP was a randomized control trial that compared intensive lifestyle intervention with placebo or masked 
metformin in an adult cohort that was determined to be at high risk for the development of diabetes. At the end of the DPP, all 
participants were offered lifestyle training given to the lifestyle intervention group.2 The DPPOS was very successful in maintaining a 
highly engaged cohort with 88% (2776) of the surviving DPP cohort being included.1 Per the SORT criteria, this is Level 2 evidence.12  
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The DPPOS1 observed there was no significant difference in the aggregate of microvascular outcomes in a patient who developed 
diabetes across all treatment arms. The number of cases of diabetes and cumulative incidence by year 15 were significantly lower by 
27 and 18% with lifestyle intervention or with metformin, respectively, compared with the placebo group. The incidence of diabetes 
in the lifestyle, metformin, or placebo groups were 480 (55%), 499 (56%), and 560 (62%), respectively. These results suggest that 
similar lifestyle intervention protocols may be beneficial in the potential reduction of long-term complications and could be 
beneficial to our patient in question. However, it should be noted that the outcome for women is a sub-group analysis and may not 
be a true difference. 
The lifestyle intervention protocol instituted as part of the DPP included a goal to maintain a weight reduction of at least 7 percent 
of initial body weight through a healthy diet, and engagement in physical activity of moderate intensity for at least 150 minutes per 
week.2 The program also included a 16-part lesson curriculum covering diet, exercise, and behavior modification which was 
administered by personal case-managers one-on-one with patients during the first 24 weeks of enrollment.2 The intensity and time 
commitment of this intervention brings into question the practicality of introducing a similar lifestyle intervention in reality. The 
intervention is particularly problematic when considering populations that resemble our patient of discussion who do not have the 
finances or time required to complete and maintain a similar program successfully. If this program were to be adapted to a more 
realistic approach it is unlikely that diet and exercise alone would be superior to medication. Hence the need in clinical practice for a 
combination of metformin as well as diet and exercise to combat microvascular complications. 
Subsequent monthly individual and group sessions were offered to reinforce the behavioral change. During the DPP Outcomes Study 
all groups (metformin, lifestyle intervention, and placebo) were offered the lifestyle intervention program quarterly during a one-
year bridge period.1 This methodology resulted in a therapeutic cross-over between treatment arms. Further, the lifestyle 
intervention during the DPP Outcomes Study1 was less intensive and resultant weight regain was observed in the lifestyle 
intervention group. The use of metformin by participants in the lifestyle and placebo groups may have also limited the magnitude of 
differences in microvascular outcomes among the three treatment arms. Once hyperglycemia worsened to FBG ≥ 7.78 mmol/L study 
drugs were discontinued, and diabetes management was transferred to a patient’s health care provider. This introduced a biased 
selection of participants who have a certain degree of glycemic control, potentially again reducing the incidence of microvascular 
complications on its own. 
The DPP Outcomes Study1 demonstrated the long-term effect of lifestyle intervention and metformin to reduce the incidence of 
diabetes. However, after 15 years of enrollment the majority of individuals in each treatment arm had developed diabetes-related 
complications. Therefore, more effective interventions are necessary. 
Clinical Application 
The study demonstrates that while lifestyle intervention can significantly reduce the incidence of diabetes, its 
effectiveness in preventing long-term microvascular complications is less convincing. However, the study’s findings 
of reduction in these complications in women show promise for patients such as ours. Ms. Berry was amenable to 
making lifestyle changes, but her socioeconomic difficulties and the lack of rigorous guided program support make 
this challenging. Unfortunately, while the patient is motivated, she is unable to commit to 150 minutes of exercise 
per week like the proposed program entails and is instead going to attempt 90 minutes a week on top of her busy 
schedule. The patient’s concern about the possible increase in doctor’s appointments if she developed additional 
symptoms of uncontrolled diabetes should be considered. Thus, the relative safety of metformin as well as our 
patient’s goals and lifestyle played into the ultimate decision to use both interventions 
The effectiveness of implementing a radical lifestyle intervention as described in the DPP Outcomes Study is 
questionable. However, the article did address our clinical question and its application can now be further 
examined under the scrutiny of food insecurity in at-risk persons and the recommendations to be made in the 
clinical setting for diabetes prevention. 
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New Knowledge Related to Clinical Decision Science 
Although outcomes in clinical research dichotomized metformin vs. lifestyle change, in practice, patients often prefer to apply both 
interventions given the socioeconomic barriers to intensive lifestyle changes alone. As such, in this risk-benefit discussion, particular 
attention was paid to the socioeconomic barriers Ms. Berry faces that could make the necessary lifestyle modifications very difficult 
if attempted alone. Research articles did not clearly show the outcome of using both, thus in the practical clinical setting we adapted 
the independent variable to a real-life application and strongly encouraged the patient to make lifestyle changes to the best of her 
ability in addition to using metformin. Further research is required to better understand how food insecurity and socioeconomic 
status preclude the beneficial effects observed through lifestyle intervention in the prevention of microvascular consequences of 
diabetes. Narrowing approaches to care of diabetic patients based on specific research alone does a disservice to patients’ long-term 
quality of life and can hinder the achievement of their goals. 
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